**Supplementary Table 5. PRISMA checklist**

|  |  |  |  |
| --- | --- | --- | --- |
| **Section** | **Item** | **PRISMA checklist item** | **Reported on page #** |
| Title |  |  | 1 |
| Title | 1 | Identify the article as a systematic review and meta-analysis | 1 |
| Abstract |  |  | 2 |
| Brief summary | 2 | Provide a brief summary, including background, objectives, methods, results, and conclusions | 2 |
| Introduction |  |  | 3-4 |
| Objectives | 3 | Introduce the background of NAFLD and resistin, elicit the problems existing between them, and clearly state the problems to be resolved. | 4 |
| Methods |  |  | 4-6 |
| Search strategy | 4 | Retrieved database, keywords and retrieval date | 4 |
| Inclusion and exclusion criteria | 5 | Criteria for eligibility and exclusion. | 5 |
| Data extraction and quality assessment | 6 | Methods of data extraction and quality evaluation | 5 |
| Statistical analysis | 7 | Specific methods of data analysis, including software, criteria for analysis, and methods for dealing with heterogeneity | 5-6 |
| Results |  |  | 6-9 |
| Included studies | 8 | Number and type of included studies and participantsand relevant characteristics of studies | 6-7 |
| Synthesis of results | 9 | Results for main outcomes, including summary measures and confidence intervals | 7-8 |
| Heterogeneity analysis | 10 | Heterogeneity analysis methods, including sensitivity analysis, subgroup analysis and meta-regression | 8-9 |
| Discussion |  |  | 9-12 |
| Interpretation | 11 | General interpretation of the results and important implications. | 9-11 |
| Strengths and limitations | 12 | Brief summary of strengths and limitations of evidence | 11 |
|  |  |  | 11-12 |
| Conclusions | 13 | Provide a general interpretation of the results | 11 |
|  |  |  | 12 |
| Funding | 14 | Primary source of funding | 12 |

**1. The search strategy in PubMed database of this meta-analysis.**

(((((((((((((((Steatohepatitis, Nonalcoholic) OR (Steatohepatitides, Nonalcoholic)) OR (Nonalcoholic Steatohepatitides)) OR (Nonalcoholic Steatohepatitis)) OR (Nonalcoholic Fatty Livers)) OR (Nonalcoholic Fatty Liver)) OR (Livers, Nonalcoholic Fatty)) OR (Liver, Nonalcoholic Fatty)) OR (Fatty Livers, Nonalcoholic)) OR (Fatty Liver, Nonalcoholic)) OR (Nonalcoholic Fatty Liver Disease)) OR (NAFLD)) OR (Non alcoholic Fatty Liver Disease)) OR (Non-alcoholic Fatty Liver Disease)) OR ("Non-alcoholic Fatty Liver Disease"[Mesh])) AND ((((Adipocyte Cysteine Rich Secreted Protein FIZZ3) OR (Adipocyte Cysteine-Rich Secreted Protein FIZZ3)) OR (Resistin)) OR ("Resistin"[Mesh])) Filters: Humans.